Top Markets
#1 Islamic Coin Islamic Coin +151.49%
#2 DOVU DOVU +48.06%
#3 Akedo Akedo +42.30%
#4 Velvet Velvet +37.91%
#5 Black Phoenix Black Phoenix +34.36%
#6 Cross Cross +17.98%
#7 DoubleZero DoubleZero +17.92%
#8 Cap Cap +14.84%
#9 Tutorial Tutorial +10.61%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +10.25%
Coin of the day
Islamic Coin Islamic Coin
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
PHAXIAM Therapeutics S.A. PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A.

PHXM
Classement en actions #39465
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
Prix de l'action
$0.11725176
Dernière synchronisation: 2025-07-14
Capitalisation boursière
$481.50K
Changement (1 jour)
-0.20%
Changement (1 an)
0.00%
Pays
FR
Échange PHAXIAM Therapeutics S.A. (PHXM)

Catégorie

Healthcare
Ratio P/B pour PHAXIAM Therapeutics S.A. (PHXM)
Ratio P/B au August 2026 TTM : 0.02
Selon les derniers rapports financiers et le cours de l'action de PHAXIAM Therapeutics S.A., le ratio cours/valeur comptable actuel (TTM) est 0.02. À la fin de 2022, le ratio P/B était de 0.48.
Historique du ratio P/B pour PHAXIAM Therapeutics S.A. de 2016 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
2026 (TTM) 0.02 -97.64%
2023 0.78 60.84%
2022 0.48 -77.96%
2021 2.20 -55.37%
2020 4.93 250.70%
2019 1.40 82.40%
2018 0.77 -33.59%
2017 1.16 -62.33%
2016 3.08 0.00%
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.2613 33,928.80%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.3483 34,401.63%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.634 19,650.00%
BE